Business
Spectral announces distribution agreement for Endotoxin Activity Assay (EAA(TM)) with Estor, SpA, in Italy
Spectral announces distribution agreement for Endotoxin Activity Assay (EAA(TM)) with Estor, SpA, in Italy.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\nTORONTO, June 22 /CNW/ - Spectral Diagnostics Inc.(\"Spectral\"), (TSX:\nSDI), today announced the signing of a distribution agreement for commercial\nsales of its novel sepsis test, the Endotoxin Activity Assay (\"EAA(TM)), in\nItaly. Estor, SpA (\"Estor\"), a leading supplier of in vitro diagnostic\ntechnologies, will distribute Spectral's new assay instrument and its reagents\nfor use in emergency departments and intensive care units. Estor is also the\nexclusive Italian distributor of Toray Medical's endotoxin removal system.\nSpectral entered into a combined diagnostic and therapeutic strategic alliance\nwith Toray earlier this month for the management of severe sepsis.\n\n\"We are very pleased to be working with Estor to distribute our sepsis\nassay throughout Italy. The EAA (TM) has been evaluated successfully in a\nnumber of hospitals in Italy over the last year. Estor will be distributing a\nnext generation platform for the assay which is small and simpler to operate,\nallowing access to new markets for the test\", stated Dr. Paul Walker,\nPresident and CEO of Spectral.\n\nSpectral is a developer of innovative technologies for rapid diagnostics.\nSpectral provides accurate and timely information to clinicians enabling the\nearly initiation of appropriate and targeted therapy. Current products include\nrapid diagnostics for sepsis (EAA(TM)) and West Nile Virus as well as a range\nof other biological reagents. Spectral's common shares are listed on The\nToronto Stock Exchange: SDI.\n\nInformation in this news release that is not current or historically\nfactual information may constitute forward-looking information within the\nmeaning of securities laws. Implicit in this information, the future outlook\nof Spectral and anticipated events or results are assumptions based on beliefs\nof Spectral's senior management as well as information currently available to\nit. While these assumptions were considered reasonable by Spectral at the time\nof preparation, they may prove to be incorrect. Readers are cautioned that\nactual results are subject to a number of risks and uncertainties, including\nthe availability of funds and resources to pursue R&D projects, the successful\nand timely completion of clinical studies, the ability of Spectral to take\nadvantage of business opportunities in the biomedical industry, the...